Skip to search formSkip to main contentSkip to account menu

pegnivacogin

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

RB 006

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes
Background: Residual platelet reactivity is a predictor of poor prognosis in patients with acute coronary syndromes (ACSs… 
Highly Cited
2016
Highly Cited
2016
Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer.
2016
2016
An anticoagulant too good to be true for revascularisation
2016
2016
Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons.
OBJECTIVES Heparin and protamine are standard for anticoagulation and reversal for cardiopulmonary bypass (CPB). The REGADO… 
Highly Cited
2015
Highly Cited
2015
Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
2014
2014
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
AIMS We sought to determine the feasibility of conducting percutaneous coronary intervention (PCI) in high-risk acute coronary… 
Highly Cited
2013
Highly Cited
2013
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary…
AIMS We sought to determine the degree of anticoagulation reversal required to mitigate bleeding, and assess the feasibility of… 
2012
2012
A phase 1 ascending dose study of a subcutaneously administered factor IXa inhibitor and its active control agent
Summary.  Background:  The REG2 anticoagulation system consists of pegnivacogin, a subcutaneously administered aptamer factor IXa… 
2011
2011
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.
AIMS Establishing factor IX inhibition in patients with acute coronary syndrome/non-ST-elevation myocardial infarction (ACS… 
2011
2011
Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial…
We performed detailed pharmacokinetic and pharmacodynamic modeling of REG1, an anticoagulation system composed of the direct… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)